We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Advisory Committee on Medicines Scheduling (ACMS #22)
Substance | Interim Decision |
---|---|
Hyaluronic acid |
Schedule 4 - Amend EntryHYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation. The proposed implementation date is 1 June 2018. |
Cardarine |
Schedule 10 - New EntryCARDARINE. Index – New EntryCARDARINE The proposed implementation date is 1 June 2018. |
Stenabolic (SR9009) |
Schedule 4 - New Entry# STENABOLIC (SR9009) and other synthetic REV-ERB agonists. Appendix D, Part 5 - New EntrySTENABOLIC (SR9009) and other synthetic REV-ERB agonists. Index – New EntrySTENABOLIC (SR9009) and other synthetic REV-ERB agonists Schedule 4 The proposed implementation date is 1 June 2018. |
Ibutamoren |
Schedule 4 - New Entry# IBUTAMOREN. Appendix D, Part 5 – New EntryIBUTAMOREN. Index – New EntryIBUTAMOREN Schedule 4 The proposed implementation date is 1 June 2018. |
alpha-Pyrrolidinovalerophenone (alpha-PVP) and related substances methylone and synthetic cathinones |
Schedule 9 - New EntryALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP). Schedule 9 - New EntryMETHYLONE *(MDMC). Schedule 9 - Amend EntryCATHINONES except when separately specified in these Schedules. Index - Amend EntryCATHINONES The proposed implementation date is 1 June 2018. |
Ibuprofen |
The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate |
Melanotan II |
Schedule 4 - New EntryMELANOTAN II. Index - New EntryMELANOTAN II Schedule 4 The proposed implementation date is 1 June 2018. |
Orphenadrine |
The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate. |
Clotrimazole |
The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate. |